|
Kevin B. Bacon, Ph.D.
Founder, CSO and Head of Research & Development
Dr. Bacon founded Actimis as a spin-off from Bayer
Yakuhin Ltd.’s Respiratory Research Department
in Kyoto, Japan. Dr. Bacon was most recently Vice President for
Respiratory diseases research with line and matrix management
responsibilities for respiratory small molecule therapeutic development
company-wide. Dr. Bacon was also involved in establishing and
managing major corporate collaborations and partnerships (Oxford
Glycosciences, Entelos, Lion, Galapagos Genomics, Inc., as well
as numerous academic and Institutional collaborations). Prior
to joining Bayer in 1999, Dr. Bacon was Associate Director of
Immunology at Neurocrine Biosciences, Inc., in San Diego, and
from 1994 to 1997 a Visiting Scientist at the DNAX Institute
for Molecular Biology (a subsidiary of Schering Plough), in Palo
Alto. Dr. Bacon received his B.Sc. and Ph.D. in Pharmacology
from the University of London (King’s College and United
Medical and Dental Schools of Guy’s and St. Thomas’,
respectively) and following post-doctoral studies, joined the
Glaxo Institute for Molecular Biology (now Serono) in Geneva,
Switzerland as a staff scientist focused on inflammation research.
Dr. Bacon has published over 100 original manuscripts, book chapters
and reviews and has been a regular contributor of original research
to the field of chemokine biology since its inception with specific
interest, and pioneering many studies, in the signaling mechanisms
of these molecules and their biological roles in cells of the
immune system.
Taro Inaba
Director
Mr. Inaba is Head of Global Bio-Pharma Team and Investment Partner at Mitsui Ventures responsible for investments in the biotechnology and life science spaces both in the US and Asia. He has seventeen years experience in investment and business development in both the life science and chemical industries. He serves as a board member for Mitsui Ventures' three existing portfolio firms and is responsible for all the 12 Mitsui Ventures biotechnology and life science portfolio firms. He holds a Bachelor of Engineering from Kyoto University and an MBA from European University in Lisbon, as well as a CFA charter.
Peter C. M. McWilliams, Ph.D.
Chairman and Acting Chief Executive Officer
Dr. McWilliams is a Principal of Sanderling
Ventures, the lead investor of Actimis Pharmaceuticals, and
brings with him more than fifteen years of experience in biomedical research
and management. In addition to Actimis Pharmaceuticals, Dr. McWilliams
also serves in the capacity of Director, Chief Executive Officer and member
of the management team in several other Sanderling portfolio companies.
Prior to joining Sanderling, Dr. McWilliams worked at Genentech where,
as a Product Manager in Oncology Commercial Development, he managed a pipeline
of oncology products in clinical and pre-clinical development and was the
Commercial Team Leader for Avastin™. Prior to that he was an Associate
with Booz.Allen & Hamilton in San Francisco where he focused on projects
for major US and International life science companies. From 1991 to 1994
he worked for Oxford Molecular, one of the first companies in the field
of rational drug design and bio-informatics, helping to set up and establish
their US operations prior to their successful IPO on the London Stock Exchange
in 1994. Dr. McWilliams received an M.B.A. from Columbia Business School
in 1996, where he was an R.C. Kopf Fellow and was elected to Beta Gamma
Sigma. He received a Ph.D. in 1991 and an M.A. in 1990 in Chemistry from
Princeton University where he received a Hugh Scott Taylor fellowship.
He received a B.A. in Natural Sciences from Cambridge University in 1987.
Fred Middleton
Director
Fred Middleton is a Managing Director of Sanderling
Ventures and has over twenty-five years experience in the
biotechnology and biomedical industries in both corporate management and
as an institutional investor. Mr. Middleton joined Sanderling in late 1987
as a General Partner and since then he has focused on venture capital investments
and the corporate development of early-stage biomedical companies, serving
as a founder, management team member and director of numerous start-up
ventures in the Sanderling portfolio. Over the last several years, he has
played active management roles as Chairman, CEO or Director of a number
of Sanderling portfolio companies. Mr. Middleton began his career as a
consultant in McKinsey & Company's San Francisco office and was also
a Vice President of Chase Manhattan Bank in New York. In 1978, Mr. Middleton
joined Genentech, Inc. to become part of the original management team and
served as Vice President of Finance, Administration, Corporate Development,
as well as Chief Financial Officer. While at Genentech, Mr. Middleton completed
over $200 million in corporate partnering and institutional funding transactions,
including the Company's initial public offering in 1980. In 1984, Mr. Middleton
founded Morgan Stanley Ventures, serving as managing general partner of
an institutional fund raised to sponsor R&D funding arrangements at
leading technology companies in the biomedical sciences and information
technology fields. Mr. Middleton earned a B.S. in chemistry from the Massachusetts
Institute of Technology in 1971 and an M.B.A with distinction from Harvard
Business School in 1973.
|
